On May 23, 2018, we published revised versions of our Privacy Policy and User Agreements. Please read these updated terms and take some time to understand them. Your use of our services is subject to these revised terms.
Yes, I Agree.

Champignon Brands Inc. (CSE: SHRM) (OTC: SHRMF) (FWB: 496) Poised to Rapid Growth in the Burgeoning Psychedelics Market

  • SHRM completed successful IPO, raising $2.8 million; lists its stocks in the U.S. and Germany
  • Unlike rapidly declining general market, nascent industry reports rapid growth, yet few players occupy the space
  • SHRM well positioned to capitalize on the burgeoning market, placed ahead of scarce competition

Champignon Brands Inc. (CSE: SHRM) (OTC: SHRMF) (FWB: 496) is a Canadian research-driven company specializing in the formulation of medicinal-mushroom health products, and novel delivery platforms for the pharmaceutical and nutraceutical industries. SHRM is poised for rapid growth as the emerging psychedelics sector has been on the rise amid volatility that is taking place in the global financial markets.

Champignon is a pioneer in the nascent psychedelics industry that has bucked the trend, sparking what could become the beginning of a gold rush in a new industry full of similarities to the cannabis industry just before the boom. SHRM’s product portfolio consists of premium, organic, sustainable mushroom formulations, led by the flagship brand, Vitality Superteas, which revolutionizes conventional organic tea through the infusion of artesian mushrooms with medicinal properties.

SHRM recently successfully completed its IPO in February 2020, raising more than $2.8 million. The company will remain focused on developing its mushroom-infused portfolio and e-commerce infrastructure in the first quarter of 2020.

To create its exclusive Vitality Superteas brand, Champignon engaged mycologists as well as health and wellness professionals to formulate several premium fungi extracts, intending to biosynthesize pharmaceutical-grade psilocybin, a compound found in medicinal mushrooms, and then optimize and scale production in a clinical setting. During the third quarter of 2020, SHRM plans to start with clinical trials, developing both nonhallucinogenic and hallucinogenic therapies psychedelic substances.

“We are dedicated to transforming the health and wellness industry via the infusion of our proprietary blend of medicinal mushrooms,” SHRM CEO Gareth Birdsall stated in a news release (http://cnw.fm/rod6Q). “The overall product portfolio is tailored for conscious consumers looking to support mental health and bolster cognitive performance through medicinal mushroom-based products. We believe that we are only scratching the surface when it comes to unlocking the benefits hidden in medicinal mushrooms.”

Champignon Brands recently listed its stocks on the U.S. OTC Markets Exchange and Germany’s Frankfurt Stock Exchange, in addition to its original listing on the Canadian Securities Exchange, expecting that the triple listing may afford shareholders exceptional liquidity while contributing to the company’s global presence. As the growing psychedelics industry is still early in its infancy, stocks such as SHRM are likely to be in high demand.

Champignon is well positioned to capitalize on the flourishing craft-mushroom market, offering current and prospective investors the gateway to a high-growth investment, particularly valuable in the current rapidly declining global financial markets. SHRM operates in the global functional food market, which is expected to reach $34 billion by 2024, and the company has performed well in the first week following its IPO, with analysts expecting this trend to continue (http://cnw.fm/S4uCT). As the sector is still in its infancy with few stocks publicly trading, Champignon offers an attractive opportunity for investors seeking high-growth potential stocks to offset the general declining market trend.

For more information, visit the company’s website at www.ChampignonBrands.com

NOTE TO INVESTORS: The latest news and updates relating to SHRM are available in the company’s newsroom at http://cnw.fm/SHRM

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have a questions or are you interested in working with CNW? Ask our Editor

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is part of the InvestorBrandNetwork.

Archives

Select A Month

Official NewsWire Relationships

Benzinga Cannabis Capital Conference Cannabis Business Summit & Expo 2019 Cannabis Drinks Expo Cannabis World Congress & Business Exposition MjMicro Conference New England Cannabis Network O'Cannabiz Conference & Expo USA CBD Expo

CannabisNewsWire Currently Accepts

Bitcoin

Bitcoin

Bitcoin Cash

Bitcoin Cash

Ethereum

Ethereum

Litecoin

Litecoin

USD Coin

USD Coin

Contact us: 303.498.7722